Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2+ Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT01196390
What this trial is testing

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Who this might be right for
Esophageal AdenocarcinomaGastroesophageal Junction AdenocarcinomaStage IB Esophageal Cancer AJCC v7+4 more
National Cancer Institute (NCI) 203
Testing effectiveness (Phase 2)Ended earlyNCT03241810
What this trial is testing

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Elevation Oncology 22
Testing effectiveness (Phase 2)Looking for participantsNCT07766018
What this trial is testing

Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Stemline Therapeutics, Inc. 70
Testing effectiveness (Phase 2)Looking for participantsNCT07394218
What this trial is testing

CtDNA-guided Treatment Decision-making

Who this might be right for
Metastatic Breast Cancer ( HER2 Negative)ctDNA
Fudan University 122
Testing effectiveness (Phase 2)Study completedNCT01885013
What this trial is testing

Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients

Who this might be right for
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 126
Testing effectiveness (Phase 2)UnknownNCT05792410
What this trial is testing

A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.

Who this might be right for
HER2 Low Advanced or Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 300
Large-scale testing (Phase 3)Study completedNCT01564056
What this trial is testing

Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment

Who this might be right for
Breast Cancer
UNICANCER 1,989
Very early researchStudy completedNCT01875666
What this trial is testing

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

Who this might be right for
Breast Neoplasms
UNC Lineberger Comprehensive Cancer Center 26
Testing effectiveness (Phase 2)UnknownNCT06470672
What this trial is testing

Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Breast CancerHormone-receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
Fudan University 32
Large-scale testing (Phase 3)Looking for participantsNCT05891093
What this trial is testing

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Who this might be right for
Breast Cancer
Fudan University 766
Testing effectiveness (Phase 2)Study completedNCT01828021
What this trial is testing

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

Who this might be right for
Breast Cancer
MacroGenics 25
Not applicableUnknownNCT05649163
What this trial is testing

Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy

Who this might be right for
HER2Advanced Gastric CancerAdvanced Gastroesophageal Junction Adenocarcinoma+1 more
Shen Lin 306
Not applicableLooking for participantsNCT06892093
What this trial is testing

Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients

Who this might be right for
HER2-positive Breast CancerDiarrhea Caused by DrugNeratinib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 308
Not applicableUnknownNCT05535621
What this trial is testing

68Ga-HER2 Affibody PET/CT Imaging for HER2-Positive Cancer Patients

Who this might be right for
HER2-Positive Cancer
Tongji Hospital 100
Very early researchLooking for participantsNCT06822998
What this trial is testing

HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
HighField Biopharmaceuticals Corporation 10
Large-scale testing (Phase 3)Active Not RecruitingNCT02246621
What this trial is testing

Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

Who this might be right for
Breast Cancer
Eli Lilly and Company 493
Testing effectiveness (Phase 2)Study completedNCT00194714
What this trial is testing

Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab

Who this might be right for
HER2/Neu PositiveHLA-A2 Positive Cells PresentStage IV Breast Cancer+1 more
University of Washington 22
Testing effectiveness (Phase 2)Ended earlyNCT05188209
What this trial is testing

Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.

Who this might be right for
Advanced or Metastatic Gastric CancerAdvanced or Metastatic Gastroesophageal Junction Carcinoma
Lepu Biopharma Co., Ltd. 6
Not applicableUnknownNCT05750693
What this trial is testing

PIK3CA in HER2+ BC and pCR Trial

Who this might be right for
HER2-positive Breast Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 58
Not applicableStudy completedNCT04756921
What this trial is testing

18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response

Who this might be right for
HER2-positive Breast Cancer
Biyun Wang, MD 30
Next Page